Assembly Biosciences, Inc. reported progress in its clinical development of antiviral candidates, with data from multiple programs expected in 2025. Specifically, interim Phase 1b data for long-acting ...
Werewolf Therapeutics updates on clinical trials, financial results, and plans for proprietary T cell engager development amidst strong cash position. Werewolf Therapeutics, Inc. announced significant ...
Delays on construction projects can cost thousands of dollars per day, yet the way teams track site progress often lags the pace at which decisions need to be made. Even $100M-plus builds still rely ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback